Efficacy of common embolic materials for bronchial artery embolization treatment in hemoptysis patients—based on Angio-CT: a retrospective study

To evaluate the safety, efficacy, and long-term prognosis of gelatin sponge (GS), polyvinyl alcohol (PVA), or their combined use for bronchial artery embolization (BAE) in patients with hemoptysis treated in an angiography-computed tomography (Angio-CT) suite. A total of 76 patients with hemoptysis between January 2020 and June 2024 were divided into three groups: the GS group ( n = 23), the PVA group ( n = 26), and the combined group ( n = 27). All patients underwent routine preoperative computed tomography angiography (CTA) and received BAE in an Angio-CT suite. Etiology and hemoptysis volume, number of embolized arteries, procedure-related complications, follow-up information, clinical success rate, recurrence rate, hemoptysis-free survival, and overall survival were recorded and assessed. There were no statistical differences among the GS, PVA, and combined groups in clinical success rate (91.3% vs. 96.2% vs. 96.3%, P = 0.679). The 6-month hemoptysis recurrence rates were 30.4% (7/23), 19.2% (5/26), and 3.7% (1/27) in the GS, PVA, and combined groups, respectively (nominal P = 0.041). Overall survival did not differ significantly among the three groups ( P = 0.364), whereas a nominal difference in hemoptysis-free survival was observed in the combined group versus the GS and PVA groups (nominal P = 0.021). No serious adverse reactions occurred during follow-up. In this retrospective cohort, the combined group showed a lower observed recurrence rate and a nominally longer hemoptysis-free survival than the GS and PVA groups. However, these findings should be interpreted as exploratory and hypothesis-generating because this was a single-center, retrospective, non-matched study with small group sizes, and the nominal P values would not be considered definitive after conservative multiplicity correction. No serious adverse reactions occurred, and overall survival did not differ among groups.

Authors

Institutions

Publication Details

Journal
BMC Pulmonary Medicine
Published
2026-09-21
DOI
https://doi.org/10.1186/s12890-026-04763-5
Primary Topic
Vascular Anomalies and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Efficacy of common embolic materials for bronchial artery embolization treatment in hemoptysis patients—based on Angio-CT: a retrospective study

Chuansheng Zheng, Yanqiao Ren, Chao Chen, Guofeng Zhou et al.
BMC Pulmonary Medicine
Vascular Anomalies and Treatments
article

Efficacy of common embolic materials for bronchial artery embolization treatment in hemoptysis patients—based on Angio-CT: a retrospective study

Chuansheng Zheng, Yanqiao Ren, Chao Chen, Guofeng Zhou, Shanshan Jiang, Xiangjun Dong, Ningjun Yu, Yi Li
article en

Abstract

To evaluate the safety, efficacy, and long-term prognosis of gelatin sponge (GS), polyvinyl alcohol (PVA), or their combined use for bronchial artery embolization (BAE) in patients with hemoptysis treated in an angiography-computed tomography (Angio-CT) suite. A total of 76 patients with hemoptysis between January 2020 and June 2024 were divided into three groups: the GS group ( n = 23), the PVA group ( n = 26), and the combined group ( n = 27). All patients underwent routine preoperative computed tomography angiography (CTA) and received BAE in an Angio-CT suite. Etiology and hemoptysis volume, number of embolized arteries, procedure-related complications, follow-up information, clinical success rate, recurrence rate, hemoptysis-free survival, and overall survival were recorded and assessed. There were no statistical differences among the GS, PVA, and combined groups in clinical success rate (91.3% vs. 96.2% vs. 96.3%, P = 0.679). The 6-month hemoptysis recurrence rates were 30.4% (7/23), 19.2% (5/26), and 3.7% (1/27) in the GS, PVA, and combined groups, respectively (nominal P = 0.041). Overall survival did not differ significantly among the three groups ( P = 0.364), whereas a nominal difference in hemoptysis-free survival was observed in the combined group versus the GS and PVA groups (nominal P = 0.021). No serious adverse reactions occurred during follow-up. In this retrospective cohort, the combined group showed a lower observed recurrence rate and a nominally longer hemoptysis-free survival than the GS and PVA groups. However, these findings should be interpreted as exploratory and hypothesis-generating because this was a single-center, retrospective, non-matched study with small group sizes, and the nominal P values would not be considered definitive after conservative multiplicity correction. No serious adverse reactions occurred, and overall survival did not differ among groups.

BMC Pulmonary Medicine
Union Hospital (HK), Sichuan Cancer Hospital (CN), Huazhong University of Science and Technology (CN)
Good health and well-being
Openalex Percentile: Top 11%
Vascular Anomalies and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.